Fungal Surveillance in Bangladesh

Launched by INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH · Oct 23, 2023

Keywords

ClinConnect Summary

The Fungal Surveillance in Bangladesh trial is a study aimed at detecting harmful fungal infections in hospitalized patients. Researchers will collect samples like blood, urine, and respiratory fluids from patients at two major hospitals in Bangladesh. These samples will be tested to identify specific types of fungi that can cause serious infections, especially in patients with weakened immune systems.

To be eligible for this trial, participants must be hospitalized and have certain health conditions that make them more susceptible to fungal infections, such as chronic lung diseases, diabetes, or those receiving chemotherapy. Children under five years old can also participate if they show signs of severe infections and meet specific health criteria. Participants will provide consent, and the study team will explain the process. This research is important as it aims to improve the understanding and management of fungal infections in vulnerable patients, helping to ensure better healthcare outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Inclusion criteria:
• Must include all of the following criteria:
• • 1. Admitted/hospitalized patients of any age and gender in tertiary-level acute care hospitals AND
• 2. Having any of the following co-morbid immunosuppressive conditions or risk factors for healthcare-associated fungal infections such as:
• • Chronic lung conditions including asthma, COPD
• • Hemodialysis patients,
• • diabetes,
• • Patients receiving chemotherapy or immunosuppressive drugs (e.g. corticosteroids, immunosuppressive drugs among organ transplant recipients), for ≥7 days
• • Patients with AIDS
• • Patients at risk of healthcare-associated infections (e.g., Patients under postoperative care, having a urinary catheter, with tracheal intubation, under ventilatory support, secured with intravenous (IV) cannula, any other invasive procedures, etc.)
• • Hospitalized Patients under prolonged injectable antibiotic treatment (\>7 days)
• • Prolonged hospitalization more than 7 days.
• • History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization
• • AND
• • 3. Patients or caregivers providing consent
• For children aged \<5 years, the age criteria and additional inclusion criteria will be as follows:
• • 0 to 59-month-old children of either sex admitted in hospital with any illness.
• • Have features of sepsis/pneumonia (based on clinical features below)
• And any of the following criteria:
• • Those who will fail to respond to injectable antibiotics or both 1st and 2nd line antibiotics (1st line- inj. Ampicillin plus gentamicin, 2nd line- inj. Ceftriaxone plus levofloxacin/gentamicin as per icddr,b hospital protocol)
• • Any child with SAM or h/o recent measles or any condition that may induce immune suppression plus fail to respond to injectable antibiotics/ 1st line antibiotics (1st line antibiotics- inj. Ampicillin +inj. Gentamicin)
• • Those who will develop late-onset hospital-associated infection (LOHAI)
• • Any child who will require ICU care for more than 7 days
• • Develop extensive thrush after taking long-term injectable antibiotics
• • History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization
• Exclusion Criteria:
• • History of taking antifungal drugs within 2 weeks
• • Not willing to give consent